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Autoimmunity is caused by loss of tolerance, whereby the immune system fails to 
distinguish self from non-self. The autoimmune panorama entails more than 100 
diseases that collectively affect close to 5% of the total population, with a higher 
prevalence in women than in men. Depending on which tissues are targeted, 
autoimmunity is classified as organ-specific or systemic. For unknown reasons, 
organ-specific autoimmunity often targets the endocrine system, leading to organ 
failure and lifelong need of hormone replacement.  
Most autoimmune diseases show familial clustering, but co-aggregation of different 
disorders in family members, and co-occurrence of multiple diseases in a single 
individual, is also common. This points to shared etiologies in autoimmunity. Twin 
studies can help explain to what extent genetic and environmental influences 
contribute to differences in traits, and can thus provide a framework for genetic 
studies. In autoimmunity, twin studies have helped explain genetic contributions 
(heritability) for some diseases, but for many they are still lacking. In other scientific 
fields, twin studies have also been used to shed light on disease overlap, but no 
attempts of explaining clustering of autoimmunity using twins have been published.  
In this thesis we explore different aspects of organ-specific autoimmunity. In Study 
I, we use the Swedish Twin Registry to demonstrate that the heritability for 
Addison’s disease is very high, making it suitable for further genetic studies. In 
Study II we use national health registries to explore cardiovascular morbidity for 
Addison’s disease, and show that women are at increased risk of cardiac events. We 
also demonstrate a dose-dependent correlation between adrenal hormone 
replacement-therapy and risk of cardiovascular disease. Study III addresses genetic 
versus non-genetic components to clustering in seven autoimmune diseases, and we 
find evidence of genetic factors explaining co-aggregation. In Study III we also 
validate previous estimates of heritability in autoimmunity by using a larger cohort 
of twins than ever before used. In Study IV, we take a closer look at Hashimoto’s 
thyroiditis and Graves’ disease, again using twins. Results imply that they are 
distantly related diseases, in contrast with current dogma. We also find that 
heritability is higher in men than in women, most notably for Hashimoto’s 
thyroiditis. This could mean that the mechanisms leading to disease differ between 
the sexes. 
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1.1.1 The discovery of autoimmunity 
Prevention of infectious disease, through discrimination of self from non-self is the 
critical task of the immune system. Failure to do so, and the ensuing consequences 
were hypothesized by Paul Ehrlich at the turn of the nineteenth century. He coined 
the condition we today know as autoimmunity “horror autotoxicus”, and predicted 
that is was a biological impossibility. Over the following decades mounting 
evidence in support of a misdirected immune response sometimes targeting own 
tissues had little scientific impact, and it was not until the early 1960s that the 
concept of autoimmunity was fully accepted. 
Today we know that approximately 5% of the global population will suffer from 
autoimmune disease (AID) at some time in life [1, 2]. While some AIDs are 
transient, most are chronic, often manifesting at a young age, leading to considerable 
morbidity over time.  
The original definition of what constitutes autoimmunity, based on the Koch’s 
postulate of infections, was outlined by Witebsky [3]. He stated that autoimmunity 
was the result of an autoantibody or cell-mediated immune reaction; that a 
corresponding antigen-target could be identified, and that transfer of autoantibodies 
would induce a similar response in experimental animals. Over the years increased 
understanding of immune mechanisms such as naturally occurring autoantibodies, 
T-cell mediated disease, and delineation of autoimmunity from autoinflammation 
has led to revisions of this definition [4, 5]. 
Direct evidence of autoimmunity through transfer of autoantibodies is rare. We are 
limited to a select few experiments of nature for such proof: neonatal forms of 
Graves’ disease (GD), Myasthenia gravis and Pemphigus vulgaris are all caused by 
transplacental passage of autoantibodies from the mother to the fetus, demonstrating 
transfer of autoimmunity [6]. However, most autoimmune phenotypes are caused by 
autoantigen-specific T-cells rather than antibodies, and human-to-human transfer of 
disease is rarely feasible [7, 8], making direct evidence difficult to obtain. 
Sometimes, animal-models can provide conceptual evidence, but for many diseases 
the link to an autoimmune etiology hinges on circumstantial evidence such as 
infiltration of immune cells in tissue samples taken from affected individuals, 
response to immunosuppressant therapy, strong association to HLA genotypes, or 
co-aggregation with other AIDs [4].  
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1.1.2 Systemic and organ-specific autoimmunity 
Depending on the tissues targeted, AIDs are classified as either systemic or organ-
specific, with the former affecting tissues in multiple organs and the latter restricted 
to single organs. The distinction is far from clear-cut, and not mirrored in distinct 
etiologies, as both organ-specific and systemic diseases sometimes overlap in 
families and individuals. It is also important to note that T-cell mediated and 
autoantibody-driven diseases are found in both systemic and organ-specific 
autoimmunity [6]. For unknown reasons, endocrine organs are often the target in 
organ-specific autoimmunity. Based on data from the Danish population, 
endocrinopathies account for approximately 30% of the total autoimmune burden 
[1]. 
In systemic autoimmunity, therapy is focused on disease modulation. Similar 
strategies, and attempts of altogether reversing the destructive process through 
immunomodulation, have been tried in organ-specific diseases such as type-1 
diabetes (DM-1) and Addison’s disease (AD), but with limited success [9]. 
Consequently, some 130 years after the introduction of thyroid extracts for treating 
myxedema [10], clinical strategies in endocrine autoimmunity are still centered 
around adequate hormone replacement.  
1.1.3 Gender-differences in autoimmunity 
For most AIDs there is a clear sex-difference in prevalence, with females more 
affected than males (Figure 1). The severity of autoimmune manifestations from the 
same disease may also differ between the sexes [11].The underlying mechanisms are 
only partly understood, but both genetic and non-genetic effects have been 
suggested. Minor differences in how males and females react to common infections, 
with a stronger cellular and humoral response in women, have been shown [12]. 
Mechanisms related to sex hormones, X-chromosome inactivation, and 
microchimerism (transfer of cells from the fetus to the mother and vice-versa during 
pregnancy), among others, have also been suggested [11], but the net effect in terms 




Figure 1. Prevalence of autoimmune diseases in Denmark by sex. Adapted from J. Autoimmun. 
2007;29(1):1. Eaton et al. Epidemiology of autoimmune diseases in Denmark with permission from 
Elsevier. 
1.1.4 Co-occurrence and co-aggregation of autoimmunity 
Co-occurrence, defined as multiple traits occurring in one individual, is not 
uncommon in autoimmunity. This is most striking in rare monogenic disorders [13]. 
Autoimmune polyendocrine syndrome type-1 (APS-1), first summarized in a case 
series in 1956 [14], is a case in point. Here, multiple AIDs, including primary 
hypoparathyroidism and AD, typically manifest at an early age along with other 
phenotypic criteria [15]. However, most AIDs are complex disorders, with multiple 
genetic and environmental factors contributing to disease, and sometimes to co-
occurrence of diseases. On an individual level, we usually cannot predict the onset 
of autoimmunity, or which AID will develop, but patterns of co-occurrence vary, 
where some AIDs rarely overlap whereas isolated disease is the exception in others 
[2].  
Co-aggregation, defined as either identical or related traits recurring in family 
members of index cases, is also common in autoimmunity, with multigenerational 
pedigrees often displaying a variety of manifestations (Figure 2) [16, 17]. Co-
aggregation implies a shared etiology, but families typically share both genes and 
environment, and discriminating genetic from non-genetic influences requires 




Figure 2. Co-aggregation of autoimmune diseases in a family pedigree. Two members of the family 
are patients of the author of this thesis. 
1.2 MODEL DISEASES FOR ORGAN-SPECIFIC AUTOIMMUNITY 
1.2.1 Addison’s disease 
AD is caused by an autoimmune destruction of the adrenal cortex. This results in 
loss of glucocorticoid and mineralocorticoid production which is universally fatal 
without adequate hormone substitution [18]. AD is a rare disorder, with prevalence 
estimates ranging from 5/100 000 in Japan to approximately 20/100 000 in the 
Scandinavian countries [19-27]. Monogenic AD due to APS-1 accounts for a small 
minority of cases, whereas sporadic (complex) disease is more common. Similar to 
APS-1, individuals with complex AD often develop autoimmune comorbidities,  
[28-30] (Figure 3) in what constitutes autoimmune polyendocrine syndrome type 2 
(APS-2)[15]. Despite different etiologic origins, autoantibodies against 21-
hydroxylase (21OH), a key-enzyme in the steroid synthesis, is a hallmark of both 
monogenic and complex AD. The female to male ratio of complex AD is 
approximately 3:2, with incidence rates peaking between 30-50 years of age [30].  
Glucocorticoid replacement therapy in AD typically consist of hydrocortisone 
tablets twice or thrice daily with doses amounting to 20-30 mg/day [31]. Intermittent 
oral dosing does not restore diurnal patterns of cortisol release, with peak levels 
early in the morning and then gradually decreasing serum concentrations with a 
nadir around midnight [32]. Mineralocorticoid replacement typically consist of 
fludrocortisone 0.1 mg once daily. For women, with no gonadal source of 
testosterone, adrenal destruction also leads to androgen deficit. Several small 
randomized trials have examined the effects of treatment with the weak androgen 
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demonstrate improvements in somatic parameters or well-being [33-36]. DHEA is 
therefore used sparingly in Sweden today. In addition to androgen deficit, a minority 
of women with AD also develop primary ovarian insufficiency, preceded by 
autoantibodies against side-chain cleavage enzyme, leaving them deplete of sexual 
hormones without adequate substitution [30]. 
1.2.2 Autoimmune thyroid diseases 
Hashimoto´s thyroiditis (HT), initially defined as lymphadenoid goiter without any 
reference to thyroid function [37], is nowadays generally used to describe chronic 
autoimmune hypothyroidism, regardless of thyroid size. This nomenclature is used 
in this text. HT, together with autoimmune hyperthyroidism or GD, collectively 
referred to as autoimmune thyroid diseases (AITDs), represent two of the most 
common forms of autoimmunity. The prevalence of AITD has increased over recent 
decades, and now most likely exceeds 5% among women in northern-European 
countries [38, 39]. Precise estimates are lacking, as a clear distinction of HT from 
subclinical hypothyroidism is hard to attain using health-registers. Moreover, 
prescription patterns indicate increased use of levothyroxine in recent years beyond 
what can be expected from an increased incidence alone [40]. Whereas AD typically 
manifests as part of APS-2, AITDs are often unique manifestations of autoimmunity 
(Figure 3). This is counter-intuitive, given that AITDs often co-occur with other 
AIDs [1, 41-45], but reflects their high prevalence compared to most other 
autoimmune disorders. Both HT and GD are more common in women than in men, 
with female to male ratios of 1:4-10 [46, 47]. This indicates that the underlying 
mechanisms leading to disease may well be different between the sexes. 
 
Figure 3. Prevalence of autoimmune co-morbidities among patients with Addison’s 












































1.3 TWIN STUDIES 
1.3.1 The evolution of twin studies 
Twin studies, whereby similarities in traits or diseases in monozygotic (MZ) and 
dizygotic (DZ) twin pairs are compared to elucidate the influence of “nature versus 
nurture”, were first envisioned in the late nineteenth century [49]. The fundamental 
twin methods used today build on models established in the 1920s and 1930s [50, 
51]. The classic twin model hinges on the assumption that MZ twins have virtually 
identical genomes, that DZ twins share on average half of their segregating alleles, 
that MZ and DZ twins share environments to an equal extent, and that twins do not 
differ from the general population with regards to the examined trait. Some of these 
assumptions have come into question [52], but on closer examination, they have 
appeared valid [53]. The value of using twin-studies to explore traits and diseases 
soon became apparent, leading to the founding of national twin registers, starting 
with the Danish Twin Register in 1954 [54]. Twin methodology has evolved over 
time, with studies in behavioral sciences, psychology and psychiatry leading the way 
[55, 56]. In these fields, similar to genetic studies, epidemiological data has been 
used not only to detect genetic influences on individual traits, but also to study the 
nature and strength of disease-overlap [57, 58]. 
1.3.2 Heritability 
A higher concordance (i.e. proportion of twins sharing a trait) in MZ than in DZ 
twins indicate that genetic effects contribute to this trait. The magnitude of genetic 
influence is often presented as heritability, a useful but sometimes misinterpreted 
statistic. The heritability of a trait is the proportion of the total variance for the trait 
in the examined population that is attributable to genetic effects. Heritability 
therefore varies from 0 to 1, sometimes presented on a percentile scale (0-100%). A 
heritability of 1 suggests that genetic effects explain all the observed variance in the 
population, whereas a heritability of 0 indicates that environmental factors are 
responsible for all observable variance.  
It is important to note that heritability does not reflect what causes a trait, only what 
causes the variation in a trait in a given population at a given point in time. 
Heritability is a group statistic, and provides no information as to the importance of 
genes in causing disease in an individual. Nor does it account for fundamental 
genetic or environmental factors shared by all individuals in the observed 
population, as they do no contribute to variance [59]. Still, estimates of heritability 
provide important information on the influence of genes in explaining how we differ 
with regards to traits and diseases.  
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1.3.3 Twin studies in autoimmunity 
The methods used for calculating heritability are best suited for traits that are 
common and rich in information, such as biometric data (height and body weight), 
or behavioral data, that can be measured on a continuous or ordinal scale. Under 
such circumstances estimating heritability is feasible even in cohorts of modest size. 
Unfortunately, AIDs fulfill none of these criteria, as they are all infrequent or rare, 
and typically represent dichotomies (disease or no disease) carrying little 
information. Consequently, estimating heritability for AIDs require large twin 
registries, available in recent decades only.  
The first formal assessment of heritability for an organ-specific AID was a Swedish 
twin-study on Crohn’s disease and ulcerative colitis published in 1988 [60]. Since 
then, many AIDs have been the subject of examination, but due to their low 
prevalence, estimates of heritability have generally been imprecise [61]. For other 
AIDs, estimates are still lacking. A common attribute of most AIDs so far studied is 
that heritability explains a majority of the observed variance (Table 1).  
Despite ample epidemiological data on co-occurrence and co-aggregation of AIDs, 
twin studies have not been used to quantify genetic and environmental influences on 
disease-overlap. Besides increasing our understanding of how diseases interrelate, 
studying etiologic overlap could help us predict how likely patients and their 
relatives are of developing not only single diseases, but any one in a group of closely 
related disorders. 
 
Table 1. Heritability in organ-specific autoimmune diseases 
Disease Heritability, % (95% CI)a Reference 
Type-1 diabetes 72  [62] 
 88  (78-94) [63] 
Hashimoto’s thyroiditisb  73  (46-89) [64] 
Graves’ disease  79  (64-90) [65] 
Celiac disease 57-87 [66] 
 75  (55-96) [67] 
Vitiligoc 72  [68] 
 46  (41-51) [69] 
 49 (47-51) [70] 
Crohn’s disease 100  (34-100) [60] 
 89  [71] 
Multiple sclerosis 64  (28-77) [72] 




1.4 GENETIC STUDIES IN AUTOIMMUNITY 
Among the earliest insights into the genetics of autoimmunity was the strong 
association with variants of the human leukocyte antigen-complex (HLA). These 
discoveries came about through linkage analysis in pedigrees with a high prevalence 
for the AIDs in question [73, 74]. Haplotypes in the HLA-region typically confer the 
largest risk in complex AIDs, making them easier to identify, whereas other allelic 
variants are harder to detect. Consequently, few other genes were identified using 
these methods [75]. Instead, candidate gene approaches helped progress the 
understanding of autoimmunity [76], and in the last two decades genome wide 
association studies (GWAS) and whole genome sequencing has added to the list of 
polymorphisms associated with AIDs [77]. Most of the alleles identified in organ-
specific autoimmunity locate to genetic regions involved in regulation of the 
adaptive immune response [78], whereas only a small minority locate to genes 
specific to the target tissue itself [79, 80]. Interestingly, most loci are pleiotropic, 
influencing the risk of more than one AID [81, 82], hinting at a partly shared genetic 
origin contributing to overlap in autoimmunity. This is also consistent with the 
autoimmune clustering observed in individuals and in families [1, 2, 16, 83, 84]. 
1.5 ETIOLOGY OF ORGAN-SPECIFIC AUTOIMMUNE DISEASES 
1.5.1 Addison’s disease 
Primary adrenal insufficiency due to APS-1 is caused by mutations in the 
autoimmune regulator gene (AIRE) [85, 86], whereas sporadic AD is a complex 
disease, with a non-Mendelian pattern of inheritance. HLA DR3-DQ2 and DR4 are 
the predominant risk factors in sporadic AD [87-89], but several other loci involved 
in immune regulation have been implicated. These include allelic variants of the 
CTLA4 [90-92], PTPN22 [93], BACH2 [94, 95] and most recently the AIRE-gene 
[96]. Most, but not all [95, 96] of these alleles have been identified through 
candidate-gene studies based on findings in other autoimmune diseases, including 
thyroid disorders (Table 2). So far, no GWAS in AD has been published.  
Familial aggregation of complex AD has been shown in both Norwegian and 
Swedish cohorts [29, 30], and several case-reports describe concordance for AD in 
monozygotic twin pairs [97-100]. These data, in line with studies demonstrating 
high heritability for other AIDs, indicate genetic influence on the occurrence of AD. 
So far, no environmental factors have been credibly linked to AD, and no formal 





Table 2. Non-HLA genes associated with organ-specific autoimmunity 
Gene Autoimmune disease 
 Addison’s disease 
Hashimoto’s 
thyroiditis Graves’ disease 
Other organ-specific 
autoimmune diseases 
CTLA4 [101] [102, 103] [104, 105] Type-1 diabetes, myasthenia gravis, vitiligo [106] 
PTPN22  [101] [107, 108] [109, 110] Type-1 diabetes, celiac disease, multiple sclerosis [108, 110, 111] 
BACH2  [94, 95] - [112] Type-1 diabetes, Crohn’s disease, celiac disease, vitiligo [113, 114] 
CLEC16A [115] [116] - Type-1 diabetes, multiple sclerosis [117, 118] 
Examples of genes implicated in Addison’s disease, autoimmune thyroid diseases and other organ-
specific autoimmune diseases.  
1.5.2 Autoimmune thyroid diseases 
Epidemiologic data on the contribution of genetic and non-genetic factors to HT and 
GD mostly stem from studies of the Danish Twin Registry [64, 65, 119, 120]. These 
report a heritability of 79% (95% CI 64-90%) for GD. Estimates of heritability for 
overt HT are lacking, but heritability for autoantibodies against thyroid peroxidase 
(TPOab) and thyroglobulin (TGab) in euthyroid subjects explain 73% (95% CI 46-
89%) of observed variance. Iodine-intake and smoking are known to have 
substantial influence on the risk of AITDs [121, 122], but still, environmental 
factors explain only modest proportions of variance (21% for GD and 27% for HT). 
The Danish study on euthyroid subjects reported a lower heritability for TGab in 
men compared to women [64], but so far, no study on overt thyroid disease has been 
powered to detect etiologic differences between the sexes. 
Extrapolating the heritability of overt HT from data on thyroid autoantibodies is not 
without risks, something the authors of the Danish twin study point out [64]. Not all 
individuals with titers against thyroid autoantigens progress to overt HT [39], and 
neither TPOab nor TGab are unique to HT, as they are common in patients with GD 
as well [123]. Moreover, autoantibodies can arise from different etiologies, 
exemplified by 21OH autoantibodies found in both APS-1 and APS-2, and 
rheumatoid factor found in both systemic lupus erythematosus and juvenile 
idiopathic arthritis despite little genetic overlap [82].  
Linkage- and candidate-gene studies have been relatively successful in identifying 
susceptibility-loci in AITD. Both gene-variants central to immune regulation and to 
thyroid function have been associated with increased risk of disease [124]. GWAS 
have helped validate previous findings and added to the list, with loci related to the 
HLA-complex, PTPN22, CTLA4 and FCRL3 and FOXE1 among others implicated 
in more than one GWAS [125]. 
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1.5.3 Etiologic overlap in autoimmune thyroid diseases 
HT and GD are generally considered to be closely related diseases [124, 126-128], 
and many features do indeed support a common etiology: transition from one 
disease to the other does occur [129, 130], family-studies have demonstrated 
accumulation of both diseases in relatives of index cases [48, 131, 132], and MZ 
twin pairs with HT in one twin and GD in the other twin have been reported [133-
135]. Furthermore, genetic overlap is evident from GWAS-data [125], and TPOab 
and TGab, a hallmark of HT, are found in patients with GD as well.  
However, there are features suggestive of separate etiologies: the phenotype in GD 
is autoantibody-mediated, whereas HT results from cytotoxic destruction of the 
thyroid gland. As previously stated, shared autoantibody-profiles are not 
synonymous with a shared etiology either, and while GWAS-data is consistent with 
genetic overlap, the proportion of heritability so far explained by pleiotropic loci is 
small. Moreover, many of the genes implicated are also relevant to other AIDs, 
supporting a broad autoimmune tautology rather than a common genetic origin to 
AITDs (Table 2). Still, without objective estimates of disease-overlap, this remains 
speculative. 
1.6 CARDIOVASCULAR COMORBIDITY IN ADDISON´S DISEASE. 
For AD, cohorts large enough to explore long-term outcomes have only emerged 
over the last two decades, and many fundamental questions related to health are still 
unanswered. For AITDs, many of these questions have been addressed [136-140], 
and will therefore not be discussed further in this thesis. 
After the introduction of glucocorticoid and mineralocorticoid replacement in the 
1950s, patients diagnosed with AD were generally considered at modestly increased 
risk of death, primarily due to acute adrenal crises[141]. This notion was challenged 
in 2006, with a population-based Swedish study demonstrating that mortality was 
more than twice that in the general population[142]. Diagnostic records did not 
provide clear answers as to why, but cardiovascular and infectious diseases appear to 
explain most of the excess mortality [142, 143]. DM-1, present in approximately 
10% of the Swedish AD-population [30], is associated with cardiovascular disease, 
but adjusting for diabetes had marginal impact on results [142]. Data from Norway 
have partially corroborated these observations, demonstrating no overall increase in 
mortality, but with an increased risk of cardiovascular death among individuals 
diagnosed with AD before the age of 40 years [144].   
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Concerns of a possible connection between glucocorticoid replacement-doses and 
cardiovascular disease (CVD) has emerged over time [141, 145, 146]. Prolonged 
exposure to high doses of glucocorticoids is known to increase cardiovascular risks 
[147], and glucocorticoid replacement doses in AD are generally much higher than 
physiological release of cortisol [148, 149]. Data on secondary adrenal insufficiency 
caused by pituitary diseases also points to a dose-associated increase in risk of death 
[150, 151]. The effects of fludrocortisone on cardiovascular outcomes in AD have 
not been discussed or explored in a wider context, despite the obvious risks 
associated with primary aldosteronism [152]. Case-reports on heart failure due to 
overdosing in patients newly diagnosed with AD highlight the dangers of 
mineralocorticoid excess [153-155], but long-term outcomes of different regimens 
are unknown.  
Studies on cardiometabolic risk factors such as adiposity, glucose metabolism, lipid 
metabolism and blood-pressure have yielded conflicting data. The largest studies to 
date, reporting on Swedish patients with AD, have found increased prescriptions of 
lipid-lowering agents and antihypertensives, but lower body mass index (BMI) and 
lower blood-pressure compared to controls [26, 30]. In other cohorts, AD has been 
be associated with dyslipidemia, higher BMI, abdominal obesity, and poor glucose 





2.1 OVERALL AIMS 
The aim of this thesis was to explore the etiology of organ-specific autoimmune 
diseases, to quantify etiologic overlap in organ-specific autoimmunity, and to 
examine cardiovascular comorbidity in AD. 
2.2 SPECIFIC AIMS 
Study I. To estimate the heritability of AD and to explore patterns of autoimmune 
comorbidity using data from the Swedish Twin Registry. 
Study II. To examine incident cardiovascular disease (including cerebrovascular 
disease) in AD, and to investigate the effects of glucocorticoid and 
mineralocorticoid dosing. 
Study III. To estimate heritability and genetic influences on co-aggregation in seven 
organ-specific autoimmune diseases using data from the Swedish Twin Registry. 
Study IV. To estimate the heritability for HT and GD by sex, and to estimate co-
heritability between HT and GD using bivariate twin methodology.
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3 MATERIALS AND METHODS 
3.1 REGISTERS 
The Swedish personal identity number [159] allows for linkage to the National 
registries of health kept by the National Board of Health and Welfare, and to 
registers containing demographic information kept by Statistics Sweden.  
The Total Population Register (Study II) 
The Total Population Register (TPR) was started in 1968. It contains data on birth, 
death, name-change, marital status, family relationships, place of residence, and 
national and international migration. Coverage is virtually complete [160].  
The Swedish National Patient Register (Study I-IV) 
The Swedish National Patient Register (NPR) contains inpatient information dating 
back to 1964, with nationwide coverage since 1987. It collects data on hospital 
admission dates, discharge dates, discharge codes and procedural codings for 
surgery classified according to the International Statistical Classification of Diseases 
(ICD). As of 2001, data on hospital-based outpatient care (but not primary 
healthcare) is also included. The diagnostic accuracy is generally very good [161]. 
The Swedish Prescribed Drug Register (Study I-IV) 
The Swedish Prescribed Drug Register (SPDR) contains data on all prescription 
drugs dispensed in Sweden from July 2005 onwards [162]. It includes information 
on dispensed quantity, dosage, and type of drug classified according to the 
Anatomical Therapeutical Chemical (ATC) classification system. It does not include 
information on drugs used for inpatient care or drugs sold over the counter. Unlike 
the NPR which does not include information on primary health care, the PDR 
includes information on all drugs dispensed. 
The Cause-of-death Registrer (Study II) 
The cause-of-death registry (CDR) contains data since 1961 on all deceased persons 
who at the time of death were registered in Sweden. Recorded variables include 
underlying cause of death, multiple causes of death, nature of injuries associated 
with death, and basis for statement of cause of death. Diagnoses are coded according 
to the international version of the ICD. Coverage is >99.5% [163]. Diagnostic 
accuracy is acceptable for deaths related to cancer and ischemic heart diseases (80-




The Swedish Twin Registry (Study I, III, IV) 
The Swedish Twin Registry (STR) is the world’s largest twin resource. It was 
started in the late 1950s and to date contains information on more than 216,000 
individual twins born in Sweden between 1886 and 2015 [165]. The registry is 
voluntary with legal guardians usually contacted by the time twins turn 9 years of 
age. Historically, coverage has been very high, but it has dropped in recent years 
[165]. Zygosity has been determined for more than 86,000 twin pairs using a 
validated intra-pair similarity algorithm, DNA, or being of opposite sex. The STR 
conducts regular updates of national health data on twins that have at some point 
agreed to participate in studies. Biobank material (saliva, capillary blood or venous 
blood) is available for more than 50,000 twins. 
The National Diabetes Register (Study III, IV) 
The National Diabetes Register (NDR) is a health quality register established in 
1996 for the purpose of collecting information on and monitoring diabetes care 
[166]. It documents health data including type of diabetes, therapy, and 
complications on an individual level. The NDR is maintained by the Swedish 
Society for Diabetology with financial support from all Swedish regions. Coverage 
is nationwide and nearly complete. 
3.2 CASE ASCERTAINMENT 
Adrenal failure is a heterogenic condition with many potential mechanisms of 
disease. Secondary failure due to pituitary or hypothalamic diseases, and long-term 
glucocorticoid treatment are common causes of adrenal malfunction. Trauma, 
infectious diseases, and genetic conditions can also lead to adrenal. Not even 
autoimmune adrenal failure is not synonymous with complex AD. The different 
forms are easily mixed up, resulting in erroneous ICD-coding. Moreover, if AD 
cannot be confirmed or rejected without confirmatory testing, is sometimes ICD-
coded as AD pending further investigation. This leaves traces in the NPR that cannot 
be erased. A Norwegian study using hospital records as gold standard for diagnosing 
AD reported a positive predictive value (PPV) of 87% for ICD-codes indicating AD 
[144], whereas a Swedish study found that 28% of patients with a diagnosis of AD 
in the NPR also had diagnostic records suggestive of pituitary disease or other 
conditions associated with AD (unpublished data from [26]). To further improve 
diagnostic accuracy, investigators in the Swedish study excluded patients without 
filled prescriptions of glucocorticoids and mineralocorticoids in the SPDR. By 
default, this excluded approximately 12% of true AD cases that do not use 
mineralocorticoids [30], but the cohort dropped by 40% in size, indicating that 
misclassification is very common. We adopted a similar strategy, but required 
multiple (≥2) prescriptions of mineralocorticoids for inclusion (Study I-III). 
However, among patients with samples in the STR-biobank (Study I, III), presence 
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or absence of 21OH autoantibodies in serum were used to validate AD regardless of 
substitution therapy. 
For GD, a corresponding ICD-code was used for inclusion unless diagnostic records 
indicated other forms of hyperthyroidism (Study I, III-IV). In Study I, III-IV, a 
diagnosis of HT required a corresponding ICD-code provided diagnostic records did 
not indicate other causes of hypothyroidism. For patients alive in 2006, with the 
SPDR in operation, multiple (≥2) dispensations of levothyroxine (ATC H03AA) 
were required to validate a diagnosis of HT. In the absence of ICD-codes for HT or 
other causes of hypothyroidism, multiple prescriptions of levothyroxine were 
sufficient for a diagnosis of HT in patients with concurrent DM-1 or AD, as HT is 
often not coded in this setting. In Study II, individuals with a diagnosis of HT in the 
NPR or with multiple (≥2) dispensations of levothyroxine in the SPDR fulfilled 
criteria for HT if they did not have diagnostic records indicating other causes of 
hypothyroidism. 
Celiac disease (CD), vitiligo (VI), atrophic gastritis and pernicious anemia (both 
referred to as AG) were ascertained through recordings of relevant ICD-codes in the 
NPR. ICD-codes indicating non-autoimmune etiology were used as exclusions to 
improve diagnostic accuracy. Multiple (≥2) prescriptions of vitamin B12 (ATC 
B03BA) were required for a diagnosis of AG in patients alive in 2006 (Study III).  
If patients had multiple (≥2) correct ICD-codes, multiple (≥2) exclusion codes were 
required for exclusion (Study III-IV).  
In Study I, a diagnosis of DM-1 was based on a corresponding ICD code in 
combination with multiple (≥2) filled prescriptions of insulin for patients alive in 
2006. In Study II, DM-1 was defined by a corresponding ICD-code. Among 
subjects with ICD-codes for both DM-1 and Type-2 diabetes (DM-2), the last 
recorded diagnosis before start of follow-up was considered correct. All other 
subjects with multiple fillings of antidiabetic agents were considered to have DM-2. 





3.3 STATISTICAL METHODS 
Tetrachoric correlations 
A commonly used measure of co-variance for dichotomous traits is the tetrachoric 
correlation. When analyzing tetrachoric correlations the liability threshold model 
may be used, whereby dichotomous outcomes are assumed to reflect an underlying 
normally distributed liability that is due to multiple genetic and environmental 
factors. This distribution is assumed to have a mean 0 and a variance 1 in the general 
population. Individuals above a certain threshold will develop the disease, whereas 
individuals below the threshold will not. The correlation is then calculated as the 
similarity between twins within pairs, by zygosity (Figure 4). A higher tetrachoric 
correlation in MZ than in DZ pairs is indicative of genetic influences [59]. This 
metric is the basis of subsequent calculations of heritability. 
 
Figure 4. Tetrachoric correlation of twin pair data with dashed 
lines indicating thresholds of normally distributed liabilities. 
Structural equation modeling 
Under the assumption of the classic twin model (outlined in section 1.3.1), the 
observed variance of a trait can be decomposed into four variance components: 
additive genetic factors (A), non-additive genetic factors due to dominance or 
epistasis (D), environmental factors that are shared by twins in a pair (C), and 
environmental factors that are unique to individuals (E). Using structural equation 
modeling, explanatory models based on these sources of variance are tested to find 
the model with the best fit [52]. Combinations of (C) and (D) are confounded in 
twins and cannot be estimated simultaneously. Hence, the ACE-model accounting 
for common environmental influences (C) or the ADE-model that considers genetic 













the estimate of (A) is equal to the narrow sense heritability h2, calculated from 
additive genetic (a2), common environmental (c2), and unique environmental (e2) 
components of variance as follows: 
h2 = a2 / (a2 + c2 + e2)  
When using the liability-threshold model for dichotomous traits, variance = 1, 
hence: 
a2 + c2 + e2 = 1;  h2 = a2 
By excluding components of variance from the full models, submodels (typically 
AE and E) are tested to find the best-fitting model. In twin studies on AIDs, more 
often than not, the AE-model has provided the best fit [63, 65, 167, 168].  
 
Figure 5A. A path diagram of a univariate ACE-model in which the three latent variables influence 
variation (A = additive genetic influences, C = common environmental influences, E = unique 
environmental influences) Double-headed arrows indicate the correlations among variables in 
monozygotic (MZ) and dizygotic (DZ) twin pairs. 
Figure 5B. A path diagram of a bivariate ACE-model in an individual twin. Correlations between the 
additive genetic, shared environmental, and nonshared environmental influences are denoted by rA, rC 
and rE. The genetic correlation represents the extent to which genetic influences on trait 1 are 
correlated with genetic influences on trait 2. Though not illustrated here, there are genetic and 
environmental correlations between the two members of a twin pair for both trait 1 and trait 2. 




















When multiple traits are assessed in twin pairs, structural equation models can be 
extended to analyze the covariance between these traits (Figure 5B). In Study IV, 
we used bivariate models to explore the genetic and environmental architecture of 
disease-overlap in HT and GD 
Biometric twin models were fitted using R (R Foundation for Statistical Computing) 
in Study I, III and IV, and with OpenMx software [169] run within the R 
environment [170] in Study III and IV. 
Poisson regression 
The Poisson regression is a generalized linear model form of regression analysis 
suited for modeling count based data of rare events, as these tend to follow a Poisson 
distribution (as opposed to more common events which tend to be normally 
distributed). In Study I, Poisson regression was used to calculate the likelihood of 
MZ twin pairs developing the same disease (positive concordance), compared to DZ 
twin pairs, expressed as incidence rate ratios. 
Cox proportional hazard models 
Cox proportional hazard is a regression model used in survival analysis for 
investigating the effect of several variables upon the time a specified event takes to 
happen. In Study II, Cox regression models were used to calculate hazard ratios for 
cardiovascular events in individuals with AD compared to matched controls. To 
explore correlations between replacement therapy and cardiovascular outcomes, 
dummy variables of hormone replacement regimens stratified into low, medium or 
high doses were added to the models. In Study III and IV, Cox regression models 
were used to estimate the risk of twins developing AIDs after an AID was diagnosed 
in the co-twin. In these models, date of birth, year of start of observation, date of 
diagnosis or date of right-censoring were used as covariates. Twins were considered 




3.4 METHODS SUMMARY  
3.4.1 Study I 
By cross-matching information in the STR with the NPR we identified twins with a 
diagnosis of AD from 1964 to 2012. Among suspected cases with biobank samples, 
presence of 21OH autoantibodies was used for inclusion. Among suspected cases 
without biobank samples prescription patterns in the SPDR were used to validate a 
diagnosis of AD. We also collected information on autoimmune comorbidities. 
Based on disease patterns in MZ and DZ twins, concordance rates and heritability 
estimates were calculated, and similarities in co-occurrence of AIDs in MZ versus 
DZ pairs were explored.  
3.4.2 Study II 
All adult individuals in Sweden with a diagnosis of AD from 1964-2013 were 
identified in the NPR. The diagnosis was then validated by exclusion of individuals 
with ambiguous diagnoses in the NDR or with insufficient prescriptions of hormone 
replacement in the SPDR. Each subject with AD was matched with 10 population 
controls. Incident CVD was analyzed prospectively from 2006 to 2013, and 
correlations between glucocorticoid and mineralocorticoid intake and CVD were 
evaluated. Case-fatality rates from CVD in subjects with AD and in matched 
controls were calculated. 
3.4.3 Study III 
By cross-matching information in the STR with the NPR we identified twins with a 
diagnosis of HT, GD, VI, AG, DM-1, CD or AD from 1964 to 2015, and included 
all individuals alive (or not yet born) in 1976. Diagnoses were validated using 
prescription data in the SPDR, and by cross-matching with the NDR. Univariate 
heritability was calculated for each disease. Attempts of estimating bivariate 
heritability for disease-pairs were mainly unsuccessful due to insufficient data. 
Instead, HRs were calculated for twins developing the same or a different disease as 
compared to their co-twin, with differences between MZ and DZ pairs used to 
estimate the genetic influence on co-aggregation. 
3.4.4 Study IV 
Using the methods outlined in Study III, all twins with a validated diagnosis of HT 
or GD were identified. Univariate heritability was calculated by sex, and bivariate 
heritability was calculated to quantify genetic and non-genetic influences on the 




4.1 STUDY I 
A total of 29 individual with AD were identified in a cohort of 112,000 twins. The 
mean age at diagnosis of AD was 38 years, 15/29 (52%) of patients were female, 
and autoimmune comorbidity was present in 18/29 (62%) patients. 14 patients were 
part of MZ twin pairs, and 15 were part of DZ pairs. Five out of nine (5/9) MZ pairs 
and zero out of fifteen (0/15) DZ pairs were concordant for AD. The probandwise 
concordance for MZ twins was 0.71 (95% CI 0.40– 0.90) and the heritability was 
estimated at 0.97 (95% CI 0.88–0.99), with the AE-model providing the best fit. 
Patterns of autoimmune co-aggregation in twin pairs affected by AD differed by 
zygosity, with MZ pairs displaying a higher degree of disease-concordance (Figure 
6). This was reflected by an incidence rate ratio of 15 (95% CI 1.8–116) for MZ 
pairs becoming disease-concordant compared to DZ pairs. 
 
 
Figure 6. Organ-specific autoimmune diseases in monozygotic (1) and dizygotic (2) twin pairs with 
Addison’s disease. (A) Addison´s disease, (H) Hashimoto’s thyroiditis, (G) Grave´s disease, (D) Type-
1 diabetes, (C) celiac disease, (P) pernicious anemia, (V) vitiligo. Concordant diagnoses in bold letters. 
Disease patterns are unique for most twin sets. To conceal identity, sex is not displayed. Reprinted 



















































4.2 STUDY II 
In total, 1500 subjects with AD and 13,758 matched controls were identified using 
national health registers. Diagnostic records and prescription-patterns indicated that 
23% of patients with AD had hypertension, 12.6% had dyslipidemia and 17.7% had 
diabetes (DM-1 or DM-2) (Table 3). 
Adjusted HR for CVD among patients with AD compared to matched controls was 
1.20 (95% CI 0.95-1.51). Stratifying CVD into ischemic heart disease (IHD) and 
cerebrovascular disease (CeVD), by sex, indicated that CVD was primarily driven 
by IHD in women (Table 4). The 30-day case-fatality rate in IHD was 41% in 
patients with AD, and 28% in matched controls (p=0.04). No difference in case-
fatality rate was observed for CevD.  
The mean dispensed dose of hydrocortisone was 29.6 mg/day, and of 
fludrocortisone 0.09 mg/day, with slightly higher doses in men. Stratifying 
glucocorticoid intake into tertiles and fludrocortisone into halves revealed an 
incremental increase in aHR for CVD with higher doses. This effect was more 
pronounced in women than in men (Figure 7). 
 
COPD – Chronic obstructive pulmonary disease 
 
  
Table 3. Age and comorbidities  
 Addison’s disease Controls 
 Total Women Men Total Women Men 
Individuals, n (%) 1 500 818 (54.5) 682 (45.5) 13 758 7487 (54.4) 6271 (45.6) 
Age at start of follow-up 
median (IQR) 50 (37-63) 54 (40-67) 47 (33-59) 49 (36-62) 52 (39-65) 45 (33-57) 
Hypertension, n (%) 353 (23.5) 134 (16.4) 219 (32.1) 2 815 (20.5) 1,770 (23.6) 1,045 (16.7) 
Dyslipidemia, n (%) 189 (12.6) 113 (13.8) 76 (11.1) 1,219 (8.9) 683 (9.1) 536 (8.5) 
Diabetes, n (%) 266 (17.7) 140 (17.1) 126 (18.5) 649 (4.7) 362 (4.8) 287 (4.6) 
Hashimoto’s thyroiditis, n 
(%) 542 (36.1) 364 (44.5) 178 (26.1) 501 (3.6) 438 (5.9) 63 (1.0) 
COPD, n (%) 18 (1.2) 12 (1.5) 6 (0.9) 113 (0.8) 72 (1.0) 41 (0.7) 
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aAdjusted for diabetes and chronic obstructive pulmonary disease. bCVD included IHD and CeVD. 





Figure 7. aHRs for CVD in subjects with AD vs matched controls by sex and by 
hydrocortisone/fludrocortisone dosing. Adjusted for diabetes and COPD in all models, and tertiles 
of hydrocortisone dosing or halves of fludrocortisone dosing as appropriate. Reprinted from 
reference [172] under Creative Commons Attribution License CC-BY 4.0 
Table 4. Unadjusted and adjusted HRs for cardiovascular events in subjects with AD vs 
matched controls, stratified by sex. 





Outcome Events, n 
Events/ 
1000 PY Events, n 
Events/ 
1000 PY a HRa 95% CI p-value 
CVDb,c        
All 94 10.7 563 7.0 1.20 0.95-1.51 0.13 
Male 40 10.3 270 7.6 1.05 0.74-1.50 0.79 
Female 54 12.7 293 7.6 1.35 0.98-1.85 0.06 
IHD        
All 71 8.1 338 4.2 1.61 1.22-2.12 0.001 
Male 28 7.0 181 5.0 1.16 0.75-1.78 0.50 
Female 43 9.8 157 3.9 2.15 1.49-3.10 <0.0001 
CeVD        
All 44 5.0 343 4.3 0.88 0.63-1.23 0.46 
Male 19 4.7 144 3.9 0.88 0.53-1.50 0.63 
Female 25 5.6 199 4.9 0.88 0.56-1.37 0.57 
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4.3 STUDY III 
In a cohort of 110,814 twins we identified 3,882 individuals (3.5%) with at least one 
of the prespecified AIDs. HT was the most common disease with a prevalence of 
2,4% in women and 0.5% in men, and AD was the rarest with a total of 28 cases. 
Cross-trait concordance (different AIDs in co-twins) was found in 153 twin pairs. 
Univariate heritability was calculated for each AID, and for an aggregate 
considering all AIDs as one phenotype (Table 5). The AE-model provided the best 
fit for all diseases except for GD where the ADE was marginally better. However, 
the broad sense heritability (A+D) was similar for the AE and the ADE model, and 
we therefore only presented results from the AE models (Table 5). 
Attempts of calculating bivariate heritability for disease-pairs were mostly 
unsuccessful. Instead, familial aggregation and co-aggregation analyses were 
performed using Cox regression models. These demonstrated increased risk of not 
only diseases present in co-twins, but also of other AIDs. This effect was more 
pronounced in MZ than in DZ twins, demonstrating genetic influences on co-


















A - additive genetic effects. E - effects form unique environment, not shared by 
twins.  
  
Table 5. Estimated heritability and environmental factors from best-
fitting models. 
Disease 
Proportions of variance 
A 95% CI E 95% CI 
Hashimoto’s thyroiditis 0.64 0.58-0.70 0.36 0.30-0.43 
Atrophic gastritis 0.38 0.23-0.53 0.62 0.47-0.77 
Celiac disease 0.91 0.87-0.94 0.09 0.06-0.13 
Graves’ disease 0.60 0.49-0.71 0.40 0.29-0.51 
Type-1 diabetes 0.81 0.73-0.89 0.20 0.12-0.27 
Vitiligo 0.65 0.50-0.81 0.35 0.19-0.50 
Addison’s disease 0.97 0.91-1.00 0.03 0.00-0.09 



















Adjusted hazard ratios for developing index and non-index diseases if co-twin has 
autoimmune disease. Index disease – same disease as present in co-twin. Non-index 
disease – any of the other six diseases studied. Adjusted for date of birth, year of start of 
observation, date of diagnosis or date of right-censoring 
 
  
Table 6. Familial aggregation and co-aggregation of autoimmunity  
Index disease 
Index disease Non-index disease 
aHR 95% CI p-value aHR 95% CI p-value 
Hashimoto’s thyroiditis    




DZ 4.1 3.1-5.4 1.4 0.8-2.5 
Atrophic gastritis    




DZ 2.8 1.3-6.0 1.1 0.6-2.1 
Celiac disease    




DZ 15.8 10.3-24.4 2.6 1.5-4.4 
Graves’ disease    




DZ 2.0 0.6-6.1 1.5 0.8-2.7 
Type-1 diabetes    




DZ 10.4 4.5-23.7 2.4 1.4-4.1 
Vitiligo    




DZ 0.0 0.0-0.0 2.4 0.7-7.6 
Addison’s disease    




DZ 0.0 0.0-0.0 10.0 2.4-40.8 
Any disease    
MZ 10.1 8.4-12.2 < 0.001 n.a. - 
DZ 2.8 2.4-3.4 n.a. 
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4.4 STUDY IV 
In a cohort of 110,814 twins we identified 1,683 (1.5%) twins with HT and 558 
(0.5%) with GD. Both diseases were more common in women than in men with a 
prevalence of 24.0/1000 in women and 5.2/1000 in men for HT, and 8.9/1000 in 
women and 1.8/1000 in men for GD. HT and GD was present in 1,545 and 536 twin 
pairs respectively, with 31 pairs affected by both diseases (HT in one twin and GD 
in the other). In quantitative genetic modeling, the AE-models preferred over the 
ACE-models in both univariate and bivariate estimates of heritability. Hence, 
adjusted results from univariate AE-models are displayed in Table 7 and the 
bivariate AE-model are displayed in Figure 8. In the bivariate model, the additive 
genetic correlation (rA) amounted to 0.35 (95% CI 0.20-0.50) and the unique 
environmental correlation (rE) to -0.56 (95% CI -0.89- -0.22). The negative rE partly 
reflects the case ascertainment process, where a previous diagnosis of GD was 
considered an exclusion criterion for HT. Etiologic overlap was small, with 8% of 
observed variance for both HT and GD explained by genetic factors shared with the 
other disease, and 11% of variance explained by shared environmental factors. 
 
Table 7. Univariate estimates of explained variance for Hashimoto’s thyroiditis and 
Graves’ disease, by sex. 
 
Additive genetic effects Non-shared environmental effects 
A 95% CI p-value E 95% CI p-value 
Hashimoto’s thyroiditis       
All 0.65 (0.60-0.70)  0.35 (0.30-0.40)  




Men 0.90 (0.82-0.97) 0.10 (0.03-0.18) 
Graves’ disease       
All 0.63 (0.54-0.72)  0.37 (0.28-0.46)  




Men 0.79 (0.63-0.96) 0.21 (0.04-0.37) 
Models adjusted for age categories and sex when appropriate. p, p-value for difference between men 
and women tested using a Wald test. Age categories were < 1920, 1920-1939, 1940-1959, 1960-
1979, > 1979; except Graves’ in men, where categories were collapsed to <1940, 1940-1959, 





Figure 8. A - additive genetic effects. E – environmental effects not shared by 

















Hashimoto's thyroiditis Graves' disease
Explained variance Hashimoto’s thyroiditis Graves’ disease
A
Total 0.65 (0.61-0.70) 0.63 (0.55-0.72)
Shared 0.08 (0.01-0.15) 0.08 (0.01-0.14)
Not shared 0.57 (0.49-0.66) 0.56 (0.44-0.67)
E
Total 0.35 (0.30-0.40) 0.37 (0.28-0.46)
Shared 0.11 (-0.02-0.24) 0.11 (-0.02-0.25)




5.1 HERITABILITY IN ORGAN-SPECIFIC AUTOIMMUNITY 
Combining phenotypical data with information on family-relations has helped us 
understand a great deal of how genes influence traits at a population-level. Most’s 
AIDs so far explored are relatively common. AD on the other hand is rare, and even 
with a large twin registry such as the STR, we barely had enough data for 
calculating heritability. Our findings in Study I of a heritability near 1 for AD 
indicates that genetics effects are responsible for nearly all the observed variance. 
However, it is important to reiterate that a high heritability does not equate to near 
Mendelian patterns of inheritance, or exclude that environmental triggers are 
necessary for developing AD. It does however indicate that genetic influences are 
important, and that GWAS or similar studies would most likely be successful in 
identifying genes important in AD. 
Current estimates of heritability for many of the AIDs so far explored stem from the 
late 1990s and the first decade of this century. The twin cohorts used back then were 
smaller than those we have at our disposal today. This forced investigators to 
extrapolate information from small cohorts od diseased twins, much like we did in 
Study I. For AD, a more precise estimate based on twin-data would require the 
combined efforts of many national registries, but for other AIDs, the STR now 
harbors a twin-cohort large enough for more precise estimates. 
In Study III, we assembled information on seven common organ-specific AIDs. For 
all AIDs, the twin-cohort provided a larger sample of affected twins than available 
in any previously published study, allowing for robust estimates of heritability. For 
VI, our results complement previous estimates from family-based studies on 
subjects of mixed ethnic origin. For AG, our estimates are the first published, but 
results should be interpreted with caution, as case ascertainment for this diagnosis is 
difficult using registry data. For most other AIDs, our results were in line with 
previous results, but with a lower level statistical uncertainty due to larger sample 
sizes. 
In Study IV, we looked in depth at the heritability of GD and HT. Our results 
suggest that genetic effects explain a larger proportion of variance in men than in 
women in both HT and GD, but the differences between the sexes were statistically 
significant for HT only. Whether different sets of genes or different magnitudes of 
effect of the same genes explain these findings is still unknown, as our data was 




5.2 CO-AGGREGATION IN ORGAN-SPECIFIC AUTOIMMUNITY 
Clustering of autoimmunity is common, but we are only just beginning to 
understand the underlying mechanisms. GWAS have provided evidence of 
pleiotropic genes influencing autoimmunity, but their combined effects explain only 
minor proportions of disease-overlap. At present, genomics has provided an 
explanatory model for how genes contribute co-aggregation in autoimmunity more 
than an actual explanation to observed variance.  
Twin studies can be used to quantify genetic and environmental components in 
disease overlap. In autoimmunity, no such attempts have been published, most likely 
due to the large cohorts needed for such undertakings. In Study I, patterns of 
autoimmune clustering in MZ twins were strikingly similar, with concordance for 20 
out of 28 autoimmune manifestations, whereas DZ twins did not display coherence 
in terms of phenotypes (Figure 6). An intriguing but speculative interpretation of 
this observation, is that pleiotropic loci interact to produce discrete risk profiles that 
are identical in MZ co-twins, but differ between DZ co-twins, consistent with the 
‘common variant/multiple disease’ hypothesis [173]. This implies that with greater 
understanding of the genetic underpinnings of autoimmunity, we would in theory be 
able to predict what AIDs may develop in individuals prone to autoimmunity. 
To further explore genetic and environmental influences on AIDs, we examined 
disease-overlap in a wider context in Study III. Overall, cross-trait concordance was 
surprisingly rare, present in only 153 out of 55,407 twin pairs (0.3%). Still, patterns 
of familial co-aggregation indicated an increased risk of both the same and of other 
AIDs than present in co-twins. Of note, co-aggregation appeared to be more 
common in MZ than in DZ pairs for most diseases, highlighting that genetic 
influences are important in co-aggregation. 
In Study IV, with sufficient data for an in-depth examination of thyroid 
autoimmunity, we performed a bivariate analysis of heritability. Our findings of 
limited etiologic overlap between HT and GD are at odds with several studies 
reporting on co-occurrence (in individuals) of AITD.  
We know that environmental triggers are essential to complex AIDs. This is 
illustrated by concordance rates for most AIDs well below 50% in MZ twins. This 
must be kept in mind when dissecting etiologic overlap using data on co-occurrence 
of diseases that affect the same organ. Both HT and GD have a profound effect on 
the thyroid gland, most likely altering expression and exposure of potential antigens. 
This could act as an environmental trigger, increasing the risk of additional thyroid 
autoimmunity. A similar mechanism is on display after radioiodine ablation of the 
thyroid gland. This leads to increased levels of circulating TRab [174], and 
sometimes induces or exacerbates thyroid associated orbitopathy [175]. 
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Family-based studies on co-aggregation are perhaps better suited for evaluating 
disease-overlap, and most so far published imply that co-aggregation is common 
[48, 176-178]. However, most of these studies rely on hospital-based sampling in 
one form or another, making them vulnerable to selection bias. The only population-
based study we have found reports a modest increase in risk of GD in probands if 
either a sibling or parent has HT [179]. Interestingly, the risk increases dramatically 
when HT is present in both a parent and a sibling. 
5.3 CARDIOVASCULAR MORBIDITY IN ADDISON’S DISEASE 
In the general population, the risk of CVD is closely linked to cardiometabolic risk 
factors such as smoking, hypertension, dyslipidemia, diabetes and obesity. Such 
factors likely contribute to the increased risk of IHD observed in Study II, but they 
do not offer a comprehensive explanation. In Study II, the use of antihypertensives 
was less common in subjects with AD compared to controls, whereas use of lipid-
lowering agents was slightly more common. We did not have information on 
smoking or obesity among study participants, but previous reports on Swedish 
patients with AD suggest that smoking is rare (4%), that obesity (BMI ≥25 kg/m2) is 
actually more common in matched controls, and that visceral fat content is similar in 
both groups [30, 180]. Diabetes, affecting nearly 18% of patients with AD in Study 
II, and only 5% of controls, is certainly responsible for part of the unadjusted risk, 
considering the high mortality observed in patients with diabetes and AD [181], but 
the increase in hazard for CVD remained after adjustment for this condition. 
Atherogenic lipid-profiles, with higher levels of triglycerides and lower levels of 
high-density lipoprotein (HDL-C) are more common in patients with AD than in 
matched controls despite more frequent use of lipid-lowering agents [157, 158, 180]. 
This could be a mediator of CVD, but does not explain the difference in outcome for 
men and women, as dyslipidemia shows no convincing sex-differences as a 
cardiovascular risk factor [182, 183].  
Concurrent autoimmunity could potentially explain the female preponderance in 
CVD. HT, more common in women than in men, and premature ovarian failure, are 
both linked to CVD. Androgen deficiency is perhaps a less appealing explanation, 
with no convincing evidence of lasting improvement in metabolic markers from 
DHEA-substitution [35, 36, 184], and with testosterone linked to shorter life spans 
in men [185]. 
Arguably, adverse effects from adrenal hormone replacement is the best explanation 
to the excess risk of IHD observed. We found an incremental increase in risk of 
CVD with higher glucocorticoid and mineralocorticoid replacement doses, and this 
effect appeared to be more prominent in women (Figure 7). 
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If other mechanisms contribute to CVD in AD is unknown, as most data on 
cardiovascular complications of glucocorticoids stem from studies on their use for 
anti-inflammatory purposes [186, 187]. Importantly, individuals included in such 
studies most likely retain an underlying capacity to secrete cortisol and maintain 
rudimentary diurnal and ultradian patterns, which is not the case in patients with 
AD. In line with our findings, over-substitution of glucocorticoids and 
mineralocorticoids may also be of greater concern in women than in men, since 
physiologic levels cortisol [188] and aldosterone [189, 190] appear to be lower in 
women. 
The lack of a significant increase in risk of CVD in the overall cohort of patients 
with AD, but large effects in subgroups calls for caution, as the risk of random 
findings increases with subgroup-analyses. What speaks in favor of a causal 
relationship between replacement therapy and CVD is the dose-dependent effect, 
and indirect evidence in support of such mechanisms from findings in similar 
diseases and treatments. This is also true for our results of increased case-fatality 
rate in patients with AD, based on quite few cases. However, we know from other 
settings that patients with AD are at increased risk of dying in case of severe illness 
[143, 144, 191], and it seems reasonable that this would be true for IHD as well. 
5.4 METHODOLOGICAL CONSIDERATIONS 
5.4.1 Internal validity 
Validation studies have indicated PPVs of 85-95% for diagnoses in the NPR, 
including AD [161]. In our experience, these numbers are overly optimistic. 
Disruption of endocrine function can occur in many different ways and at different 
levels of the hormonal axis (hypothalamic, pituitary, end-organ), but still result in 
similar phenotypes. We used strict diagnostic criteria outlined in section 3.2 to 
circumvent this problem. A challenge in validating HT is that most patients do not 
attend hospital-based clinics for thyroid check-ups, and therefore leave no diagnostic 
records in the NPR unless they seek hospital-care for other reasons. In contrast, 
liberal prescribing policies have left traces of levothyroxine-use in the SPDR for 
close to 10% of adult Swedish women (https://sdb.socialstyrelsen.se/if_lak/). 
Therefore, using prescriptions of levothyroxine to validate HT in the absence of an 
exclusion diagnosis in the NPR is still questionable. 
In all works presented in this thesis, we have used strict inclusion criteria for 
diagnoses later used as variables in analytical statistics, but taken a more relaxed 
approach with diagnostic variables used in descriptive statistics only (HT in Study 
II for example). The purpose was to maximize specificity at the cost of reduced 
sensitivity for analytical variables, as a reduced specificity would invariably have 
led to unreliable estimates of heritability and relative risks [192, 193].  
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Using the SPDR to validate AD is essential, but it is not without consequence, as it 
can introduce immortal time bias [194]. In Study II, all patients diagnosed with AD 
before the introduction of the SPDR had to be alive in 2005 for validation. This in fact 
“immortalized” them, as all patients dying before 2005 were automatically excluded. 
The obvious strategy to eliminate immortal time is to include incident cases only 
(diagnosed after 2005), but that would have left us with a cohort of only 400 patients, 
leaving the study severely underpowered. Instead, we chose to match controls and 
subjects with AD and at the date of a first diagnostic record of AD in the NPR, and to 
exclude controls dying before the start of the SPDR, in essence immortalizing them as 
well. This left us with a comparatively healthy cohort, which may have led us to 
underestimate absolute risks, but enabled us to calculate more accurate relative risks. 
5.4.2 External validity 
Estimates of heritability belong to the population on which they are based, and 
should in theory be extrapolated to other settings with caution. In reality, they have 
proven quite stable across populations with reasonably similar socioeconomic 
environments [195]. For AITDs, a cause of concern is iodine status which can have 
a significant impact on the prevalence of thyroid autoimmunity, and which does 
differ considerably between countries and regions. AITDs are also heterogenic 
across ethnicities, with slightly different genetic mechanisms contributing to disease, 
and with different disease prevalences [127, 196]. The same is true for AD, with 
considerable genetic heterogeneity between populations [197]. 
Heritability has its limitations. The most obvious is that genetic studies in medicine 
have not been able to account for more than a minority of it. This has raised 
questions about the unexplained or ‘missing heritability’. The narrow sense 
heritability (h2) rests on the assumption that alleles influence phenotypic traits 
independently of each other in an additive manner. This is not always true, gene-
gene interactions through dominance and epistasis have been demonstrated [198, 
199], but the magnitude of this effect is unknown. Gene-environment interactions 
and epigenetic effects have also been suggested as explanations to missing 
heritability [200, 201]. However, with sample-sizes in GWAS growing, larger 
proportions of heritability are explained, either by a multitude of loci with small 
individual effects, [202, 203] or by rare variants with a large impact [204]. In the 




6 CONCLUSIONS AND IMPLICATIONS 
In Study I, the probandwise concordance for AD in MZ twins was over 70%, 
meaning that co-twins of diseased twins are more likely than not to develop AD. In 
the rare instance of a MZ twin developing AD, it is therefore important to be wary of 
future symptoms consistent with AD in the co-twin. A direct consequence of a high 
MZ and low DZ concordance is that heritability will be high, for AD close to 1. This 
suggests that it is a disease well suited for future GWAS or whole genome 
sequencing.  
In Study II, we found that women with AD are at increased risk of IHD, and that 
this risk correlates with hormone replacement doses. Similar findings have been 
reported for secondary adrenal insufficiency, underscoring the importance of using 
the lowest doses compatible with well-being, and treating cardiovascular risk factors 
at an early stage, in women in particular.  
Many family studies have demonstrated overlap in AIDs, without differentiating 
genetic from environmental causes. In Study III, we provide the first objective 
evidence of genetic influences on disease clustering using epidemiological data. This 
corroborates findings from GWAS on overlap in AIDs, but more detailed studies are 
needed to better our understanding of how AIDs interrelate, and to help guide future 
genetic studies. 
In Study IV, we demonstrate that etiologic overlap in GD and HT is modest at most, 
and that they should be considered as separate diseases. Moreover, we find that 
heritability plays a larger role in men than in women with AITD. The modest 
overlap between HT and GD reported in Study IV means that cross-trait 
concordance was rare, occurring in only 31 twin pairs. While our results most likely 
suffice to rule out major genetic overlap in AITDs, they need to be validated in other 
settings. Still, future genetic studies will most likely benefit from treating GD and 
HT, in men and in women, as separate disorders. Ideally, they should be powered to 
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